
Conference Coverage
Latest News

NeuroVoices: Michio Hirano, MD, on Reflecting on Contributions to Neuromuscular Disease Research

Phase 1/2 VALOR Study to Assess ASP2957 Gene Therapy in Infants With X-Linked Myotubular Myopathy

Capricor’s DMD Cardiomyopathy Cell Therapy Deramiocel Back Under Review by FDA

Brogidirsen Demonstrates Long-Term Safety and Stable Motor Function in DMD

FDA Approves Leucovorin for Cerebral Folate Transport Deficiency

Shorts










Videos
Podcasts
Continuing Medical Education
All News

The study design of the phase 3 STELLAR trials, presented at the 2026 MDA Conference, aims to investigate salanersen among presymptomatic infants with spinal muscular atrophy.

Interim phase 2 data from the FORWARD-53 study suggest the exon-skipping therapy WVE-N531 was well tolerated and produced sustained dystrophin expression, reduced fibrosis, and functional improvements in boys with DMD amenable to exon 53 skipping.

Phase 2 CANYON data show sevasemten keeps heart function steady in Becker muscular dystrophy, with stable NT-proBNP and hints of

Here's some of what is coming soon to NeurologyLive® this week.

Polish real-world study shows children with SMA improve after switching from nusinersen or risdiplam to gene therapy, with expected side effects.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is Seronegative generalized myasthenia gravis!

PrimeC shows significant survival gains and slowed progression in ALS phase 2b follow-up, fueling plans for larger late-stage trials.

A recently published position statement from the American Headache Society recommends annual screening for migraine in girls and women, highlighting the potential role of tools like the ID Migraine screener to improve identification.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending March 6, 2026.

Large-scale proteomic and transcriptomic analyses position the synaptic protein NRN1 as a resilience-linked therapeutic candidate in Alzheimer disease, though validation remains preclinical.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Amaal Starling, MD, FAHS, FAAN. [LISTEN TIME: 16 minutes]

A Large cohort analysis of more than 159,000 adults found greater adherence to multiple healthy dietary patterns—particularly the DASH diet—was linked to a significantly lower risk of subjective cognitive decline in midlife.

Catch up on any of the neurology headlines you may have missed in February 2026, compiled into 1 place by the NeurologyLive® team.

A first-in-human SMA1 gene therapy trial doses infants with GB221 via intracisternal AAV delivery, aiming to boost motor outcomes while limiting toxicity.

A cross-sectional analysis of nearly 28,000 middle-aged adults found that excessive daytime sleepiness is strongly associated with both sleep characteristics and modifiable psychological factors, highlighting the need for integrated prevention strategies.


























